Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: OACCW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -12.09% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.36 - 1.24 | Updated Date 06/14/2025 |
52 Weeks Range 0.36 - 1.24 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Oaktree Acquisition Corp. III Life Sciences Warrant
Company Overview
History and Background
Oaktree Acquisition Corp. III was a blank check company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The warrant represented the right to purchase stock of the target company post-merger. Given the lack of information about the final acquisition and its effect on the warrant, historical data is limited.
Core Business Areas
- Acquisition Target Search: Oaktree Acquisition Corp. III's core business was searching for and acquiring a company in the life sciences sector. The warrant represents the right to purchase equity after a successful acquisition is completed.
Leadership and Structure
Oaktree Acquisition Corp. III was led by a management team associated with Oaktree Capital Management. The structure was typical of a SPAC, with a board of directors overseeing the search and acquisition process.
Top Products and Market Share
Key Offerings
- Warrant (OCTL.WS): The warrant itself represents the right to purchase shares of the post-merger company at a specified price. Its value is derived from the potential value of the underlying shares. Market share data isn't applicable to warrants directly, but the warrant's price reflects market sentiment about the success of the underlying target company.
Market Dynamics
Industry Overview
The SPAC market experienced significant growth and subsequent volatility. Life sciences companies remain a popular target for SPAC mergers due to innovation in this space.
Positioning
Oaktree Acquisition Corp. III was positioned to leverage Oaktree's expertise and network to identify and acquire a promising life sciences company.
Total Addressable Market (TAM)
The TAM is the total market value of the entire life sciences sector. Oaktree Acquisition Corp. III positioned itself by focusing on identifying a specific, lucrative niche within that broader TAM.
Upturn SWOT Analysis
Strengths
- Experienced Management Team
- Strong Financial Backing from Oaktree Capital Management
- Focus on Life Sciences Sector
Weaknesses
- Dependence on Identifying and Completing a Successful Acquisition
- SPAC Market Volatility
- Dilution from Warrant Exercise
Opportunities
- Acquire a High-Growth Life Sciences Company
- Capitalize on Market Demand for Life Sciences Investments
- Generate Significant Returns for Shareholders
Threats
- Inability to Find a Suitable Acquisition Target
- Competition from Other SPACs
- Unfavorable Market Conditions
Competitors and Market Share
Key Competitors
Competitive Landscape
Oaktree Acquisition Corp. III competed with other SPACs seeking targets in the life sciences sector. The competitive advantage was the company's experience with the life sciences sector.
Growth Trajectory and Initiatives
Historical Growth: Growth depended on the acquired company's performance.
Future Projections: Future projections depended on the acquired company's market position, growth potential, and integration strategy.
Recent Initiatives: Recent initiatives depended on the acquired company, which is not publically available.
Summary
Oaktree Acquisition Corp. III was a SPAC that focused on the life sciences industry. Its success depended on the ability to identify and acquire a promising company. Given the warrant's potential dilution to common shareholders, caution was warranted. A successful acquisition would benefit warrant holders, while a failure could lead to significant losses. Without knowledge of the final acquisition target and its execution of its business plan, the company's strength is unknown.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Market Data Providers
Disclaimers:
This analysis is based on publicly available information and general knowledge of SPACs. It does not constitute financial advice. Information about the target company post merger is unavailable and may affect the accuracy of this analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oaktree Acquisition Corp. III Life Sciences Warrant
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2024-12-16 | CEO & Director Mr. Zaid Pardesi | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.